CAR-T Meeting 2025 | The T-FITNESS consortium: developing a novel CAR-T using microRNA synthetic circuits
In this video, Luca Gattinoni, MD, Leibniz Institute for Immunotherapy, Regensburg, Germany, provides a brief introduction to the T-FITNESS consortium. This initiative aims to develop a novel CAR T-cell therapy with enhanced efficacy against solid tumors using microRNA synthetic circuits. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
T-FITNESS is a European consortium that was funded through the EIC Pathfinder Challenge of 2021. It is a consortium that involves multiple European countries including Spain, Italy, France, Switzerland, Germany and Slovenia. The focus of the consortium is to develop a novel CAR T-cell therapy with enhanced efficacy against a solid tumor. We aim to do this by developing microRNA synthetic circuits that prevent the induction of exhaustion program in T-cells...
T-FITNESS is a European consortium that was funded through the EIC Pathfinder Challenge of 2021. It is a consortium that involves multiple European countries including Spain, Italy, France, Switzerland, Germany and Slovenia. The focus of the consortium is to develop a novel CAR T-cell therapy with enhanced efficacy against a solid tumor. We aim to do this by developing microRNA synthetic circuits that prevent the induction of exhaustion program in T-cells. So we aim to make T-cells refractory to T-cell exhaustion using this type of circuits.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
LG has a patent application for the use of mitochondrial transfer technology in cancer immunotherapies.
